These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
x
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
¨
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Delaware
|
|
94-1622541
|
|
(State or other jurisdiction of
|
|
(I.R.S. Employer
|
|
incorporation or organization)
|
|
Identification No.)
|
|
Large accelerated filer
x
|
|
Accelerated filer
¨
|
|
|
|
|
|
Non-accelerated filer
¨
|
|
Smaller reporting company
¨
|
|
(do not check if a smaller reporting company)
|
|
|
|
|
|
|
Page
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
||||||||||||
|
|
July 4,
2015 |
|
June 28,
2014 |
|
July 4,
2015 |
|
June 28,
2014 |
|
||||||||
|
Net sales
|
$
|
188,502
|
|
|
$
|
196,517
|
|
|
$
|
592,838
|
|
|
$
|
589,295
|
|
|
|
Cost of sales
|
109,720
|
|
|
122,256
|
|
|
348,433
|
|
|
356,823
|
|
|
||||
|
Gross profit
|
78,782
|
|
|
74,261
|
|
|
244,405
|
|
|
232,472
|
|
|
||||
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Research and development
|
21,270
|
|
|
19,046
|
|
|
61,467
|
|
|
60,396
|
|
|
||||
|
Selling, general and administrative
|
36,154
|
|
|
37,226
|
|
|
113,777
|
|
|
116,413
|
|
|
||||
|
Impairment of investment
|
2,017
|
|
|
—
|
|
|
2,017
|
|
|
—
|
|
|
||||
|
Amortization of intangible assets
|
647
|
|
|
841
|
|
|
2,009
|
|
|
2,691
|
|
|
||||
|
Total operating expenses
|
60,088
|
|
|
57,113
|
|
|
179,270
|
|
|
179,500
|
|
|
||||
|
Income from operations
|
18,694
|
|
|
17,148
|
|
|
65,135
|
|
|
52,972
|
|
|
||||
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Interest and dividend income
|
183
|
|
|
201
|
|
|
440
|
|
|
318
|
|
|
||||
|
Interest expense
|
(4
|
)
|
|
(9
|
)
|
|
(29
|
)
|
|
(40
|
)
|
|
||||
|
Other—net
|
(787
|
)
|
|
(415
|
)
|
|
286
|
|
|
319
|
|
|
||||
|
Total other income (expense), net
|
(608
|
)
|
|
(223
|
)
|
|
697
|
|
|
597
|
|
|
||||
|
Income before income taxes
|
18,086
|
|
|
16,925
|
|
|
65,832
|
|
|
53,569
|
|
|
||||
|
Provision for income taxes
|
4,822
|
|
|
3,926
|
|
|
16,725
|
|
|
13,560
|
|
|
||||
|
Net income
|
$
|
13,264
|
|
|
$
|
12,999
|
|
|
$
|
49,107
|
|
|
$
|
40,009
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Basic
|
$
|
0.54
|
|
|
$
|
0.52
|
|
|
$
|
1.98
|
|
|
$
|
1.62
|
|
|
|
Diluted
|
$
|
0.53
|
|
|
$
|
0.52
|
|
|
$
|
1.96
|
|
|
$
|
1.60
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Shares used in computation:
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Basic
|
24,737
|
|
|
24,837
|
|
|
24,794
|
|
|
24,720
|
|
|
||||
|
Diluted
|
24,972
|
|
|
25,115
|
|
|
25,018
|
|
|
25,025
|
|
|
||||
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
||||||||||||
|
|
July 4,
2015 |
|
June 28,
2014 |
|
July 4,
2015 |
|
June 28,
2014 |
|
||||||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Net income
|
$
|
13,264
|
|
|
$
|
12,999
|
|
|
$
|
49,107
|
|
|
$
|
40,009
|
|
|
|
Other comprehensive income (loss):
(1)
|
|
|
|
|
|
|
|
|
||||||||
|
Translation adjustment, net of taxes
(2)
|
1,108
|
|
|
(800
|
)
|
|
(46,691
|
)
|
|
3,215
|
|
|
||||
|
Net gain (loss) on derivative instruments, net of taxes
(3)
|
77
|
|
|
(157
|
)
|
|
627
|
|
|
(157
|
)
|
|
||||
|
Changes in unrealized gains (losses) on available-for-sale securities, net of taxes
(4)
|
1,059
|
|
|
25
|
|
|
1,260
|
|
|
8
|
|
|
||||
|
Other comprehensive income (loss), net of tax
|
2,244
|
|
|
(932
|
)
|
|
(44,804
|
)
|
|
3,066
|
|
|
||||
|
Comprehensive income (loss)
|
$
|
15,508
|
|
|
$
|
12,067
|
|
|
$
|
4,303
|
|
|
$
|
43,075
|
|
|
|
(1)
|
Reclassification adjustments were not significant during the
three and nine months ended
July 4, 2015
and
June 28, 2014
.
|
|
(2)
|
Tax expense (benefit) of
$(98)
and
$(1,960)
was provided on translation adjustments during the
three and nine months ended
July 4, 2015
, respectively. Tax expense (benefit) of
$118
and
$1,457
was provided on translation adjustments during the
three and nine months ended
June 28, 2014
, respectively.
|
|
(3)
|
Tax expense (benefit) of
$45
and
$364
was provided on net gain (loss) on derivative instruments during the
three and nine months ended
July 4, 2015
. Tax expense (benefit) of
$(91)
was provided on net gain (loss) on derivative instruments during the
three and nine months ended
June 28, 2014
.
|
|
(4)
|
Tax expense (benefit) of
$619
and
$738
was provided on unrealized gains (losses) on available for sale securities during the
three and nine months ended
July 4, 2015
. Tax expense (benefit) on changes in unrealized gains (losses) on available-for-sale securities for the
three and nine months ended
June 28, 2014
was insignificant.
|
|
|
July 4,
2015 |
|
September 27,
2014 |
||||
|
ASSETS
|
|
|
|
|
|
||
|
Current assets:
|
|
|
|
|
|
||
|
Cash and cash equivalents
|
$
|
103,138
|
|
|
$
|
91,217
|
|
|
Short-term investments
|
233,628
|
|
|
227,058
|
|
||
|
Accounts receivable—net of allowances of $1,030 and $1,155, respectively
|
144,688
|
|
|
137,324
|
|
||
|
Inventories
|
157,778
|
|
|
170,483
|
|
||
|
Prepaid expenses and other assets
|
47,316
|
|
|
27,839
|
|
||
|
Deferred tax assets
|
24,391
|
|
|
27,134
|
|
||
|
Total current assets
|
710,939
|
|
|
681,055
|
|
||
|
Property and equipment, net
|
98,996
|
|
|
107,424
|
|
||
|
Goodwill
|
100,096
|
|
|
109,513
|
|
||
|
Intangible assets, net
|
22,163
|
|
|
31,666
|
|
||
|
Other assets
|
64,898
|
|
|
69,717
|
|
||
|
Total assets
|
$
|
997,092
|
|
|
$
|
999,375
|
|
|
|
|
|
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
||
|
Current liabilities:
|
|
|
|
|
|
||
|
Accounts payable
|
$
|
32,196
|
|
|
$
|
32,784
|
|
|
Income taxes payable
|
923
|
|
|
2,029
|
|
||
|
Other current liabilities
|
96,664
|
|
|
82,506
|
|
||
|
Total current liabilities
|
129,783
|
|
|
117,319
|
|
||
|
Long-term obligations
|
—
|
|
|
—
|
|
||
|
Other long-term liabilities
|
53,345
|
|
|
62,407
|
|
||
|
Commitments and contingencies (Note 10)
|
|
|
|
|
|
||
|
Stockholders’ equity:
|
|
|
|
|
|
||
|
Common stock, Authorized—500,000 shares, par value $.01 per share:
|
|
|
|
|
|
||
|
Outstanding—24,836 shares and 24,950 shares, respectively
|
247
|
|
|
248
|
|
||
|
Additional paid-in capital
|
174,055
|
|
|
184,042
|
|
||
|
Accumulated other comprehensive income (loss)
|
(10,122
|
)
|
|
34,682
|
|
||
|
Retained earnings
|
649,784
|
|
|
600,677
|
|
||
|
Total stockholders’ equity
|
813,964
|
|
|
819,649
|
|
||
|
Total liabilities and stockholders’ equity
|
$
|
997,092
|
|
|
$
|
999,375
|
|
|
|
Nine Months Ended
|
||||||
|
|
July 4,
2015 |
|
June 28,
2014 |
||||
|
Cash flows from operating activities:
|
|
|
|
|
|
||
|
Net income
|
$
|
49,107
|
|
|
$
|
40,009
|
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|||
|
Depreciation and amortization
|
18,453
|
|
|
20,006
|
|
||
|
Amortization of intangible assets
|
6,176
|
|
|
7,281
|
|
||
|
Impairment of investment
|
2,017
|
|
|
—
|
|
||
|
Deferred income taxes
|
5,312
|
|
|
(3,115
|
)
|
||
|
Stock-based compensation
|
13,737
|
|
|
14,207
|
|
||
|
Other non-cash (income) expense
|
8
|
|
|
(376
|
)
|
||
|
Changes in assets and liabilities, net of effect of acquisitions:
|
|
|
|
|
|
||
|
Accounts receivable
|
(15,637
|
)
|
|
5,749
|
|
||
|
Inventories
|
2,011
|
|
|
(10,262
|
)
|
||
|
Prepaid expenses and other assets
|
(21,193
|
)
|
|
(11,898
|
)
|
||
|
Other assets
|
(670
|
)
|
|
(2,714
|
)
|
||
|
Accounts payable
|
641
|
|
|
(3,855
|
)
|
||
|
Income taxes payable/receivable
|
(11,800
|
)
|
|
(13,808
|
)
|
||
|
Other current liabilities
|
19,177
|
|
|
19,944
|
|
||
|
Other long-term liabilities
|
1,496
|
|
|
3,729
|
|
||
|
Net cash provided by operating activities
|
68,835
|
|
|
64,897
|
|
||
|
|
|
|
|
||||
|
Cash flows from investing activities:
|
|
|
|
|
|
||
|
Purchases of property and equipment
|
(16,187
|
)
|
|
(17,862
|
)
|
||
|
Proceeds from dispositions of property and equipment
|
1,848
|
|
|
417
|
|
||
|
Purchases of available-for-sale securities
|
(274,832
|
)
|
|
(161,180
|
)
|
||
|
Proceeds from sales and maturities of available-for-sale securities
|
270,044
|
|
|
147,285
|
|
||
|
Net cash used in investing activities
|
(19,127
|
)
|
|
(31,340
|
)
|
||
|
|
|
|
|
||||
|
Cash flows from financing activities:
|
|
|
|
|
|
||
|
Short-term borrowings
|
24,354
|
|
|
45,927
|
|
||
|
Repayments of short-term borrowings
|
(24,354
|
)
|
|
(45,091
|
)
|
||
|
Net change in capital lease obligations
|
—
|
|
|
(2
|
)
|
||
|
Issuance of common stock under employee stock option and purchase plans
|
7,256
|
|
|
10,513
|
|
||
|
Repurchase of common stock
|
(25,009
|
)
|
|
—
|
|
||
|
Net settlement of restricted common stock
|
(5,295
|
)
|
|
(7,793
|
)
|
||
|
Net cash provided by(used in) financing activities
|
(23,048
|
)
|
|
3,554
|
|
||
|
Effect of exchange rate changes on cash and cash equivalents
|
(14,739
|
)
|
|
2,013
|
|
||
|
Net increase in cash and cash equivalents
|
11,921
|
|
|
39,124
|
|
||
|
Cash and cash equivalents, beginning of period
|
91,217
|
|
|
110,444
|
|
||
|
Cash and cash equivalents, end of period
|
$
|
103,138
|
|
|
$
|
149,568
|
|
|
|
|
|
|
||||
|
Noncash investing and financing activities:
|
|
|
|
||||
|
Unpaid property and equipment purchases
|
$
|
941
|
|
|
$
|
1,425
|
|
|
|
|
Aggregate Fair Value
|
|
Quoted Prices
in
Active Markets
for Identical
Assets
|
|
Significant
Other
Observable
Inputs
|
|
Aggregate Fair Value
|
|
Quoted Prices
in Active Markets for Identical Assets |
|
Significant
Other
Observable
Inputs
|
||||||||||||
|
|
|
July 4, 2015
|
|
September 27, 2014
|
||||||||||||||||||||
|
|
|
|
|
(Level 1)
|
|
(Level 2)
|
|
|
|
(Level 1)
|
|
(Level 2)
|
||||||||||||
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Money market fund deposits
|
|
$
|
13,187
|
|
|
$
|
13,187
|
|
|
$
|
—
|
|
|
$
|
5,975
|
|
|
$
|
5,975
|
|
|
$
|
—
|
|
|
Certificates of deposit
|
|
—
|
|
|
—
|
|
|
—
|
|
|
12,084
|
|
|
—
|
|
|
12,084
|
|
||||||
|
Commercial paper
(2)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,400
|
|
|
—
|
|
|
1,400
|
|
||||||
|
Short-term investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
U.S. Treasury and agency obligations
(2)
|
|
158,991
|
|
|
—
|
|
|
158,991
|
|
|
150,088
|
|
|
—
|
|
|
150,088
|
|
||||||
|
Corporate notes and obligations
(2)
|
|
48,317
|
|
|
—
|
|
|
48,317
|
|
|
52,987
|
|
|
—
|
|
|
52,987
|
|
||||||
|
Commercial paper
(2)
|
|
8,995
|
|
|
—
|
|
|
8,995
|
|
|
23,983
|
|
|
—
|
|
|
23,983
|
|
||||||
|
Equity securities
(1)
|
|
17,325
|
|
|
17,325
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Prepaid and other assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Foreign currency contracts
(3)
|
|
431
|
|
|
—
|
|
|
431
|
|
|
366
|
|
|
—
|
|
|
366
|
|
||||||
|
Mutual funds — Deferred comp and supplemental plan
(4)
|
|
14,626
|
|
|
14,626
|
|
|
—
|
|
|
15,000
|
|
|
15,000
|
|
|
—
|
|
||||||
|
Total
|
|
$
|
261,872
|
|
|
$
|
45,138
|
|
|
$
|
216,734
|
|
|
$
|
261,883
|
|
|
$
|
20,975
|
|
|
$
|
240,908
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Other current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Foreign currency contracts
(3)
|
|
(249
|
)
|
|
—
|
|
|
(249
|
)
|
|
(2,196
|
)
|
|
—
|
|
|
(2,196
|
)
|
||||||
|
Total
|
|
$
|
261,623
|
|
|
$
|
45,138
|
|
|
$
|
216,485
|
|
|
$
|
259,687
|
|
|
$
|
20,975
|
|
|
$
|
238,712
|
|
|
(1)
|
Valuations are based upon quoted market prices.
|
|
(2)
|
Valuations are based upon quoted market prices in active markets involving similar assets. The market inputs used to value these instruments generally consist of market yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency. Pricing sources include industry standard data providers, security master files from large financial institutions, and other third party sources which are input into a distribution-curve-based algorithm to determine a daily market value. This creates a “consensus price” or a weighted average price for each security.
|
|
(3)
|
The principal market in which we execute our foreign currency contracts is the institutional market in an over-the-counter environment with a relatively high level of price transparency. The market participants usually are large commercial banks. Our foreign currency contracts’ valuation inputs are based on quoted prices and quoted pricing intervals from public data sources and do not involve management judgment. At
September 27, 2014
, prepaid expenses and other assets include
$303
non-designated forward contracts and
$63
foreign currency contracts designated for cash flow hedges, respectively; other current liabilities include
$1,246
non-designated forward contracts and
$950
cash flow contracts, respectively. At
July 4, 2015
, prepaid expenses and other assets include
$348
non-designated forward contracts and
$83
cash flow contracts, respectively; other current liabilities include
$249
non-designated forward contracts and
$0
cash flow contracts, respectively. See Note 5, "Derivative Instruments and Hedging Activities".
|
|
(4)
|
The fair value of mutual funds is determined based on quoted market prices. Securities traded on a national exchange are stated at the last reported sales price on the day of valuation; other securities traded in over-the-counter markets and listed securities for which no sale was reported on that date are stated as the last quoted bid price.
|
|
|
July 4, 2015
|
||||||||||||||
|
|
Cost Basis
|
|
Unrealized
Gains
|
|
Unrealized
Losses
|
|
Fair Value
|
||||||||
|
Cash and cash equivalents
|
$
|
103,138
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
103,138
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Short-term investments:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Available-for-sale securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Commercial paper
|
$
|
8,995
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
8,995
|
|
|
U.S. Treasury and agency obligations
|
158,412
|
|
|
618
|
|
|
(39
|
)
|
|
158,991
|
|
||||
|
Corporate notes and obligations
|
48,187
|
|
|
194
|
|
|
(64
|
)
|
|
48,317
|
|
||||
|
Equity securities
|
15,269
|
|
|
2,056
|
|
|
—
|
|
|
17,325
|
|
||||
|
Total short-term investments
|
$
|
230,863
|
|
|
$
|
2,868
|
|
|
$
|
(103
|
)
|
|
$
|
233,628
|
|
|
|
September 27, 2014
|
||||||||||||||
|
|
Cost Basis
|
|
Unrealized
Gains
|
|
Unrealized
Losses
|
|
Fair Value
|
||||||||
|
Cash and cash equivalents
|
$
|
91,217
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
91,217
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Short-term investments:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Available-for-sale securities:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Commercial paper
|
$
|
23,983
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
23,983
|
|
|
U.S. Treasury and agency obligations
|
149,260
|
|
|
831
|
|
|
(3
|
)
|
|
150,088
|
|
||||
|
Corporate notes and obligations
|
52,834
|
|
|
195
|
|
|
(42
|
)
|
|
52,987
|
|
||||
|
Total short-term investments
|
$
|
226,077
|
|
|
$
|
1,026
|
|
|
$
|
(45
|
)
|
|
$
|
227,058
|
|
|
|
July 4, 2015
|
|
September 27, 2014
|
||||||||||||
|
|
Amortized Cost
|
|
Estimated Fair Value
|
|
Amortized Cost
|
|
Estimated Fair Value
|
||||||||
|
Investments in available-for-sale debt securities due in less than one year
|
$
|
160,201
|
|
|
$
|
160,728
|
|
|
$
|
178,329
|
|
|
$
|
179,223
|
|
|
Investments in available-for-sale debt securities due in one to five years
(1)
|
$
|
55,393
|
|
|
$
|
55,575
|
|
|
$
|
47,748
|
|
|
$
|
47,835
|
|
|
|
U.S. Notional Contract Value
|
|
U.S. Fair Value
|
||||||||||||
|
|
July 4, 2015
|
|
September 27, 2014
|
|
July 4, 2015
|
|
September 27, 2014
|
||||||||
|
Euro currency hedge contracts
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Purchase
|
$
|
20,672
|
|
|
$
|
31,926
|
|
|
$
|
(73
|
)
|
|
$
|
(1,153
|
)
|
|
|
|
|
|
|
|
|
|
||||||||
|
Japanese Yen currency hedge contracts
|
|
|
|
|
|
|
|
||||||||
|
Purchase
|
$
|
2,449
|
|
|
$
|
471
|
|
|
$
|
(32
|
)
|
|
$
|
(3
|
)
|
|
Sell
|
$
|
(5,395
|
)
|
|
$
|
(15,084
|
)
|
|
$
|
11
|
|
|
$
|
169
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Korean Won currency hedge contracts
|
|
|
|
|
|
|
|
||||||||
|
Purchase
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Sell
|
$
|
(11,073
|
)
|
|
$
|
(2,991
|
)
|
|
$
|
(86
|
)
|
|
$
|
72
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Chinese RMB currency hedge contracts
|
|
|
|
|
|
|
|
||||||||
|
Purchase
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
Sell
|
$
|
(10,051
|
)
|
|
$
|
(15,678
|
)
|
|
$
|
36
|
|
|
$
|
(56
|
)
|
|
|
|
|
|
|
|
|
|
||||||||
|
Other foreign currency hedge contracts
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Purchase
|
$
|
3,581
|
|
|
$
|
1,899
|
|
|
$
|
(15
|
)
|
|
$
|
(35
|
)
|
|
Sell
|
$
|
(6,297
|
)
|
|
$
|
(3,515
|
)
|
|
$
|
60
|
|
|
$
|
63
|
|
|
|
U.S. Notional Contract Value
|
|
U.S. Fair Value
|
||||||||||||
|
|
July 4, 2015
|
|
September 27, 2014
|
|
July 4, 2015
|
|
September 27, 2014
|
||||||||
|
Euro currency hedge contracts
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Purchase
|
$
|
—
|
|
|
$
|
11,149
|
|
|
$
|
—
|
|
|
$
|
(950
|
)
|
|
Japanese Yen currency hedge contracts
|
|
|
|
|
|
|
|
||||||||
|
Sell
|
$
|
(2,821
|
)
|
|
$
|
(12,091
|
)
|
|
$
|
(83
|
)
|
|
$
|
63
|
|
|
|
Location in financial statements
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||||||
|
|
|
July 4,
2015 |
|
June 28,
2014 |
|
July 4,
2015 |
|
June 28,
2014 |
|||||||||
|
Derivatives designated as hedging instruments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Gains(losses) in OCI on derivatives (effective portion), after tax
|
OCI
|
|
$
|
77
|
|
|
$
|
(248
|
)
|
|
$
|
627
|
|
|
$
|
(248
|
)
|
|
Gains(losses) reclassified from OCI into income (effective portion)
|
Cost of sales
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
(1,720
|
)
|
|
$
|
—
|
|
|
Gains(losses) reclassified from OCI into income (effective portion)
|
Revenue
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
208
|
|
|
$
|
—
|
|
|
Gains(losses) recognized in income on derivatives (ineffective portion and amount excluded from effectiveness testing)
|
Other income(expense)
|
|
$
|
—
|
|
|
$
|
17
|
|
|
$
|
(112
|
)
|
|
$
|
17
|
|
|
Derivatives not designated as hedging instruments
|
|
|
|
|
|
|
|
|
|
||||||||
|
Gains(losses) recognized in income
|
Other income(expense)
|
|
$
|
(29
|
)
|
|
$
|
(1,367
|
)
|
|
$
|
(6,154
|
)
|
|
$
|
(1,208
|
)
|
|
|
|
|
|
|
|
|
|
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
|
|
|
|
||||||||||||||
|
|
|
Gross Amounts of Recognized Derivative Assets
|
|
Gross Amounts Offset in the Condensed Consolidated Balance Sheets
|
|
Net Amounts of Derivative Assets Presented in the Condensed Consolidated Balance Sheets
|
|
Financial Instruments (1)
|
|
Cash Collateral Received
|
|
Net Amounts
|
|
||||||||||||
|
As of July 4, 2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Foreign exchange contracts
|
|
$
|
431
|
|
|
$
|
—
|
|
|
$
|
431
|
|
|
$
|
(131
|
)
|
|
$
|
—
|
|
|
$
|
300
|
|
|
|
As of September 27, 2014:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Foreign exchange contracts
|
|
$
|
367
|
|
|
$
|
—
|
|
|
$
|
367
|
|
|
$
|
(367
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
|
|
|
|
|
|
|
|
|
Gross Amounts Not Offset in the Condensed Consolidated Balance Sheets
|
|
|
|
||||||||||||||
|
|
|
Gross Amounts of Recognized Derivative Liabilities
|
|
Gross Amounts Offset in the Condensed Consolidated Balance Sheets
|
|
Net Amounts of Derivative Liabilities Presented in the Condensed Consolidated Balance Sheets
|
|
Financial Instruments (1)
|
|
Cash Collateral Paid
|
|
Net Amounts
|
|
||||||||||||
|
As of July 4, 2015:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Foreign exchange contracts
|
|
$
|
(249
|
)
|
|
$
|
—
|
|
|
$
|
(249
|
)
|
|
$
|
131
|
|
|
$
|
—
|
|
|
$
|
(118
|
)
|
|
|
As of September 27, 2014:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Foreign exchange contracts
|
|
$
|
(2,197
|
)
|
|
$
|
—
|
|
|
$
|
(2,197
|
)
|
|
$
|
367
|
|
|
$
|
—
|
|
|
$
|
(1,830
|
)
|
|
|
|
Specialty
Lasers and
Systems
|
|
Commercial
Lasers and
Components
|
|
Total
|
||||||
|
Balance as of September 27, 2014
|
$
|
103,150
|
|
|
$
|
6,363
|
|
|
$
|
109,513
|
|
|
Translation adjustments and other
|
(9,417
|
)
|
|
—
|
|
|
(9,417
|
)
|
|||
|
Balance as of July 4, 2015
|
$
|
93,733
|
|
|
$
|
6,363
|
|
|
$
|
100,096
|
|
|
|
July 4, 2015
|
|
September 27, 2014
|
||||||||||||||||||||
|
|
Gross
Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net
|
|
Gross
Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net
|
||||||||||||
|
Existing technology
|
$
|
76,483
|
|
|
$
|
(60,033
|
)
|
|
$
|
16,450
|
|
|
$
|
81,551
|
|
|
$
|
(57,827
|
)
|
|
$
|
23,724
|
|
|
Customer lists
|
15,237
|
|
|
(9,942
|
)
|
|
5,295
|
|
|
16,632
|
|
|
(9,199
|
)
|
|
7,433
|
|
||||||
|
Trade name
|
394
|
|
|
(345
|
)
|
|
49
|
|
|
431
|
|
|
(346
|
)
|
|
85
|
|
||||||
|
In-process research & development
|
369
|
|
|
—
|
|
|
369
|
|
|
424
|
|
|
—
|
|
|
424
|
|
||||||
|
Total
|
$
|
92,483
|
|
|
$
|
(70,320
|
)
|
|
$
|
22,163
|
|
|
$
|
99,038
|
|
|
$
|
(67,372
|
)
|
|
$
|
31,666
|
|
|
|
Estimated
Amortization
Expense
|
||
|
2015 (remainder)
|
$
|
2,082
|
|
|
2016
|
7,427
|
|
|
|
2017
|
6,409
|
|
|
|
2018
|
3,758
|
|
|
|
2019
|
1,987
|
|
|
|
2020
|
422
|
|
|
|
Thereafter
|
78
|
|
|
|
Total
|
$
|
22,163
|
|
|
|
July 4,
2015 |
|
September 27,
2014 |
||||
|
Purchased parts and assemblies
|
$
|
49,580
|
|
|
$
|
51,091
|
|
|
Work-in-process
|
61,018
|
|
|
70,486
|
|
||
|
Finished goods
|
47,180
|
|
|
48,906
|
|
||
|
Total inventories
|
$
|
157,778
|
|
|
$
|
170,483
|
|
|
|
July 4,
2015 |
|
September 27,
2014 |
||||
|
Prepaid and refundable income taxes
|
$
|
10,432
|
|
|
$
|
11,001
|
|
|
Other taxes receivable
|
23,070
|
|
|
5,184
|
|
||
|
Prepaid expenses and other
|
13,814
|
|
|
11,654
|
|
||
|
Total prepaid expenses and other assets
|
$
|
47,316
|
|
|
$
|
27,839
|
|
|
|
July 4,
2015 |
|
September 27,
2014 |
||||
|
Assets related to deferred compensation arrangements
|
$
|
26,495
|
|
|
$
|
26,484
|
|
|
Deferred tax assets
|
34,513
|
|
|
37,616
|
|
||
|
Other assets
|
3,890
|
|
|
5,617
|
|
||
|
Total other assets
|
$
|
64,898
|
|
|
$
|
69,717
|
|
|
|
July 4,
2015 |
|
September 27,
2014 |
||||
|
Accrued payroll and benefits
|
$
|
29,210
|
|
|
$
|
29,228
|
|
|
Deferred income
|
16,586
|
|
|
15,536
|
|
||
|
Warranty reserve
|
15,679
|
|
|
16,961
|
|
||
|
Accrued expenses and other
|
11,018
|
|
|
13,410
|
|
||
|
Other taxes payable
|
22,128
|
|
|
5,036
|
|
||
|
Customer deposits
|
2,043
|
|
|
2,335
|
|
||
|
Total other current liabilities
|
$
|
96,664
|
|
|
$
|
82,506
|
|
|
|
Nine Months Ended
|
||||||
|
|
July 4,
2015 |
|
June 28,
2014 |
||||
|
Beginning balance
|
$
|
16,961
|
|
|
$
|
18,508
|
|
|
Additions related to current period sales
|
16,605
|
|
|
17,990
|
|
||
|
Warranty costs incurred in the current period
|
(15,065
|
)
|
|
(18,320
|
)
|
||
|
Adjustments to accruals related to foreign exchange and other
|
(2,822
|
)
|
|
(303
|
)
|
||
|
Ending balance
|
$
|
15,679
|
|
|
$
|
17,875
|
|
|
|
July 4,
2015 |
|
September 27,
2014 |
||||
|
Long-term taxes payable
|
$
|
7,752
|
|
|
$
|
15,776
|
|
|
Deferred compensation
|
28,119
|
|
|
27,858
|
|
||
|
Deferred tax liabilities
|
5,137
|
|
|
6,511
|
|
||
|
Deferred income
|
3,397
|
|
|
3,448
|
|
||
|
Asset retirement obligations liability
|
2,125
|
|
|
2,222
|
|
||
|
Other long-term liabilities
|
6,815
|
|
|
6,592
|
|
||
|
Total other long-term liabilities
|
$
|
53,345
|
|
|
$
|
62,407
|
|
|
|
|
Employee Stock Purchase Plan
|
|
||||||||||||||
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
||||||||||||
|
|
|
July 4,
2015 |
|
June 28,
2014 |
|
July 4,
2015 |
|
June 28,
2014 |
|
||||||||
|
Expected life in years
|
|
0.5
|
|
|
0.5
|
|
|
0.5
|
|
|
0.5
|
|
|
||||
|
Expected volatility
|
|
30.8
|
%
|
|
24.2
|
%
|
|
26.8
|
%
|
|
23.9
|
%
|
|
||||
|
Risk-free interest rate
|
|
0.06
|
%
|
|
0.06
|
%
|
|
0.06
|
%
|
|
0.07
|
%
|
|
||||
|
Expected dividend yield
|
|
—
|
%
|
|
—
|
%
|
|
—
|
%
|
|
—
|
%
|
|
||||
|
Weighted average fair value per share
|
|
$
|
14.58
|
|
|
$
|
13.55
|
|
|
$
|
14.27
|
|
|
$
|
13.64
|
|
|
|
|
|
Nine Months Ended
|
||||
|
|
|
July 4, 2015
|
|
June 28, 2014
|
||
|
Risk-free interest rate
|
|
0.96
|
%
|
|
0.62
|
%
|
|
Volatility
|
|
28.7
|
%
|
|
36.9
|
%
|
|
Weighted average fair value
|
|
$70.57
|
|
$77.10
|
||
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
||||||||||||
|
|
July 4, 2015
|
|
June 28, 2014
|
|
July 4, 2015
|
|
June 28, 2014
|
|
||||||||
|
Cost of sales
|
$
|
664
|
|
|
$
|
611
|
|
|
$
|
1,937
|
|
|
$
|
1,797
|
|
|
|
Research and development
|
529
|
|
|
504
|
|
|
1,415
|
|
|
1,526
|
|
|
||||
|
Selling, general and administrative
|
3,372
|
|
|
3,552
|
|
|
10,385
|
|
|
10,884
|
|
|
||||
|
Income tax benefit
|
(1,272
|
)
|
|
(1,270
|
)
|
|
(3,005
|
)
|
|
(3,935
|
)
|
|
||||
|
|
$
|
3,293
|
|
|
$
|
3,397
|
|
|
$
|
10,732
|
|
|
$
|
10,272
|
|
|
|
|
Time Based Restricted Stock Units
|
|
Market-Based Performance Restricted Stock Units
|
||||||||||
|
|
Number of
Shares
|
|
Weighted
Average
Grant Date
Fair Value
|
|
Number of
Shares
|
|
Weighted
Average Grant Date Fair Value |
||||||
|
Nonvested stock at September 27, 2014
|
390
|
|
|
$
|
58.66
|
|
|
230
|
|
|
$
|
61.46
|
|
|
Granted
|
236
|
|
|
64.87
|
|
|
51
|
|
|
70.57
|
|
||
|
Vested
(1)
|
(218
|
)
|
|
53.61
|
|
|
(39
|
)
|
|
53.46
|
|
||
|
Forfeited
|
(11
|
)
|
|
58.78
|
|
|
(43
|
)
|
|
53.46
|
|
||
|
Nonvested stock at July 4, 2015
|
397
|
|
|
|
|
|
199
|
|
|
|
|
||
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
||||||||||||
|
|
July 4,
2015 |
|
June 28,
2014 |
|
July 4,
2015 |
|
June 28,
2014 |
|
||||||||
|
Weighted average shares outstanding —basic
|
24,737
|
|
|
24,837
|
|
|
24,794
|
|
|
24,720
|
|
|
||||
|
Dilutive effect of employee stock awards
|
235
|
|
|
278
|
|
|
224
|
|
|
305
|
|
|
||||
|
Weighted average shares outstanding—diluted
|
24,972
|
|
|
25,115
|
|
|
25,018
|
|
|
25,025
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
||||||||
|
Net income
|
$
|
13,264
|
|
|
$
|
12,999
|
|
|
$
|
49,107
|
|
|
$
|
40,009
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Net income per basic share
|
$
|
0.54
|
|
|
$
|
0.52
|
|
|
$
|
1.98
|
|
|
$
|
1.62
|
|
|
|
Net income per diluted share
|
$
|
0.53
|
|
|
$
|
0.52
|
|
|
$
|
1.96
|
|
|
$
|
1.60
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
||||||||||||
|
|
July 4,
2015 |
|
June 28,
2014 |
|
July 4,
2015 |
|
June 28,
2014 |
|
||||||||
|
Foreign exchange loss
|
$
|
(869
|
)
|
|
$
|
(736
|
)
|
|
$
|
(950
|
)
|
|
$
|
(3,248
|
)
|
|
|
Gain on deferred compensation investments, net
|
121
|
|
|
331
|
|
|
1,176
|
|
|
3,498
|
|
|
||||
|
Other
|
(39
|
)
|
|
(10
|
)
|
|
60
|
|
|
69
|
|
|
||||
|
Other - net
|
$
|
(787
|
)
|
|
$
|
(415
|
)
|
|
$
|
286
|
|
|
$
|
319
|
|
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
||||||||||||||
|
|
July 4,
2015 |
|
June 28,
2014 |
|
July 4,
2015 |
|
June 28,
2014 |
|
||||||||||
|
Net sales:
|
|
|
|
|
|
|
|
|
||||||||||
|
Specialty Laser Systems
|
$
|
123,341
|
|
|
$
|
137,590
|
|
|
$
|
408,448
|
|
|
$
|
418,208
|
|
|
||
|
Commercial Lasers and Components
|
65,161
|
|
|
58,927
|
|
|
184,390
|
|
|
171,087
|
|
|
||||||
|
Total net sales
|
$
|
188,502
|
|
|
$
|
196,517
|
|
|
$
|
592,838
|
|
|
$
|
589,295
|
|
|
||
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Income (expense) from operations:
|
|
|
|
|
|
|
|
|
||||||||||
|
Specialty Laser Systems
|
$
|
24,760
|
|
|
$
|
27,144
|
|
|
$
|
91,392
|
|
|
$
|
86,893
|
|
|
||
|
Commercial Lasers and Components
|
4,227
|
|
1,825
|
|
(162
|
)
|
|
7,209
|
|
|
15
|
|
7,209
|
|
||||
|
Corporate and other
|
(10,293
|
)
|
|
(9,834
|
)
|
|
(33,466
|
)
|
|
(33,936
|
)
|
|
||||||
|
Total income from operations
|
18,694
|
|
|
17,148
|
|
|
65,135
|
|
|
52,972
|
|
|
||||||
|
Total other income, net
|
(608
|
)
|
|
(223
|
)
|
|
697
|
|
|
597
|
|
|
||||||
|
Income before income taxes
|
18,086
|
|
|
16,925
|
|
|
65,832
|
|
|
53,569
|
|
|
||||||
|
Provision for income taxes
|
4,822
|
|
|
3,926
|
|
|
16,725
|
|
|
13,560
|
|
|
||||||
|
Net Income
|
$
|
13,264
|
|
|
$
|
12,999
|
|
|
$
|
49,107
|
|
|
$
|
40,009
|
|
|
||
|
•
|
Leverage our technology portfolio and application engineering to lead the proliferation of photonics into broader markets
—We will continue to identify opportunities in which our technology portfolio and application engineering can be used to offer innovative solutions and gain access to new markets. We plan to utilize our expertise to increase our market share in the mid to high power material processing applications.
|
|
•
|
Optimize our leadership position in existing markets
—There are a number of markets where we have historically been at the forefront of technological development and product deployment and from which we have derived a substantial portion of our revenues. We plan to optimize our financial returns from these markets.
|
|
•
|
Maintain and develop additional strong collaborative customer and industry relationships
—We believe that the Coherent brand name and reputation for product quality, technical performance and customer satisfaction will help us to further develop our loyal customer base. We plan to maintain our current customer relationships and develop new ones with customers who are industry leaders and work together with these customers to design and develop innovative product systems and solutions as they develop new technologies.
|
|
•
|
Develop and acquire new technologies and market share
—We will continue to enhance our market position through our existing technologies and develop new technologies through our internal research and development efforts, as well as through the acquisition of additional complementary technologies, intellectual property, manufacturing processes and product offerings.
|
|
•
|
Streamline our manufacturing structure and improve our cost structure
—We will focus on optimizing the mix of products that we manufacture internally and externally. We will utilize vertical integration where our internal manufacturing process is considered proprietary and seek to leverage external sources when the capabilities and cost structure are well developed and on a path towards commoditization.
|
|
•
|
Focus on long-term improvement of adjusted EBITDA, in dollars and as a percentage of net sales
—We define adjusted EBITDA as operating income adjusted for depreciation, amortization, stock compensation expenses, major restructuring costs and certain other non-operating income and expense items. Key initiatives to reach our goals for EBITDA improvements include utilization of our Asian manufacturing locations, rationalizing our supply chain and continued leveraging of our infrastructure.
|
|
|
Three Months Ended
|
|
|
|
|
|||||||||
|
|
July 4, 2015
|
|
June 28, 2014
|
|
Change
|
|
% Change
|
|||||||
|
|
(Dollars in thousands)
|
|||||||||||||
|
|
|
|
|
|
|
|
|
|||||||
|
Bookings
|
$
|
176,665
|
|
|
$
|
244,527
|
|
|
$
|
(67,862
|
)
|
|
(27.8
|
)%
|
|
Book-to-bill ratio
|
0.94
|
|
|
1.24
|
|
|
(0.30
|
)
|
|
(24.2
|
)%
|
|||
|
Net sales—Specialty Lasers and Systems
|
$
|
123,341
|
|
|
$
|
137,590
|
|
|
$
|
(14,249
|
)
|
|
(10.4
|
)%
|
|
Net sales—Commercial Lasers and Components
|
$
|
65,161
|
|
|
$
|
58,927
|
|
|
$
|
6,234
|
|
|
10.6
|
%
|
|
Gross profit as a percentage of net sales—
Specialty Lasers and Systems
|
45.4
|
%
|
|
40.9
|
%
|
|
4.5
|
%
|
|
11.0
|
%
|
|||
|
Gross profit as a percentage of net sales—Commercial Lasers and Components
|
35.8
|
%
|
|
31.6
|
%
|
|
4.2
|
%
|
|
13.3
|
%
|
|||
|
Research and development as a percentage of net sales
|
11.3
|
%
|
|
9.7
|
%
|
|
1.6
|
%
|
|
16.5
|
%
|
|||
|
Income before income taxes
|
$
|
18,086
|
|
|
$
|
16,925
|
|
|
$
|
1,161
|
|
|
6.9
|
%
|
|
Net cash provided by (used in) operating activities
|
$
|
(11,579
|
)
|
|
$
|
20,478
|
|
|
$
|
(32,057
|
)
|
|
(156.5
|
)%
|
|
Days sales outstanding in receivables
|
69.1
|
|
|
59.9
|
|
|
9.2
|
|
|
15.4
|
%
|
|||
|
Annualized third quarter inventory turns
|
2.8
|
|
|
2.7
|
|
|
0.1
|
|
|
3.7
|
%
|
|||
|
Capital spending as a percentage of net sales
|
2.1
|
%
|
|
2.0
|
%
|
|
0.1
|
%
|
|
5.0
|
%
|
|||
|
Net income as a percentage of net sales
|
7.0
|
%
|
|
6.6
|
%
|
|
0.4
|
%
|
|
6.1
|
%
|
|||
|
Adjusted EBITDA as a percentage of net sales
|
18.4
|
%
|
|
15.8
|
%
|
|
2.6
|
%
|
|
16.5
|
%
|
|||
|
|
Nine Months Ended
|
|
|
|
|
|||||||||
|
|
July 4, 2015
|
|
June 28, 2014
|
|
Change
|
|
% Change
|
|||||||
|
|
(Dollars in thousands)
|
|||||||||||||
|
|
|
|
|
|
|
|
|
|||||||
|
Bookings
|
$
|
559,741
|
|
|
$
|
707,826
|
|
|
$
|
(148,085
|
)
|
|
(20.9
|
)%
|
|
Book-to-bill ratio
|
0.94
|
|
|
1.20
|
|
|
(0.26
|
)
|
|
(21.7
|
)%
|
|||
|
Net sales—Specialty Lasers and Systems
|
$
|
408,448
|
|
|
$
|
418,208
|
|
|
$
|
(9,760
|
)
|
|
(2.3
|
)%
|
|
Net sales—Commercial Lasers and Components
|
$
|
184,390
|
|
|
$
|
171,087
|
|
|
$
|
13,303
|
|
|
7.8
|
%
|
|
Gross profit as a percentage of net sales—
Specialty Lasers and Systems
|
44.5
|
%
|
|
42.5
|
%
|
|
2.0
|
%
|
|
4.7
|
%
|
|||
|
Gross profit as a percentage of net sales—Commercial Lasers and Components
|
35.1
|
%
|
|
33.2
|
%
|
|
1.9
|
%
|
|
5.7
|
%
|
|||
|
Research and development as a percentage of net sales
|
10.4
|
%
|
|
10.2
|
%
|
|
0.2
|
%
|
|
2.0
|
%
|
|||
|
Income before income taxes
|
$
|
65,832
|
|
|
$
|
53,569
|
|
|
$
|
12,263
|
|
|
22.9
|
%
|
|
Net cash provided by operating activities
|
$
|
68,835
|
|
|
$
|
64,897
|
|
|
$
|
3,938
|
|
|
6.1
|
%
|
|
Capital spending as a percentage of net sales
|
2.7
|
%
|
|
3.0
|
%
|
|
(0.3
|
)%
|
|
(10.0
|
)%
|
|||
|
Net income as a percentage of net sales
|
8.3
|
%
|
|
6.8
|
%
|
|
1.5
|
%
|
|
22.1
|
%
|
|||
|
Adjusted EBITDA as a percentage of net sales
|
18.3
|
%
|
|
16.6
|
%
|
|
1.7
|
%
|
|
10.2
|
%
|
|||
|
|
Three Months Ended
|
|
Nine Months Ended
|
||||||||
|
|
July 4,
2015 |
|
June 28,
2014 |
|
July 4,
2015 |
|
June 28,
2014 |
||||
|
Net income as a percentage of net sales
|
7.0
|
%
|
|
6.6
|
%
|
|
8.3
|
%
|
|
6.8
|
%
|
|
Income tax expense
|
2.6
|
%
|
|
2.0
|
%
|
|
2.8
|
%
|
|
2.3
|
%
|
|
Interest and other income (expense), net
|
0.4
|
%
|
|
0.3
|
%
|
|
0.1
|
%
|
|
0.5
|
%
|
|
Depreciation and amortization
|
4.2
|
%
|
|
4.5
|
%
|
|
4.2
|
%
|
|
4.6
|
%
|
|
Customs audit
|
0.7
|
%
|
|
—
|
%
|
|
0.2
|
%
|
|
—
|
%
|
|
Impairment of investment
|
1.1
|
%
|
|
—
|
%
|
|
0.4
|
%
|
|
—
|
%
|
|
Stock-based compensation
|
2.4
|
%
|
|
2.4
|
%
|
|
2.3
|
%
|
|
2.4
|
%
|
|
Adjusted EBITDA as a percentage of net sales
|
18.4
|
%
|
|
15.8
|
%
|
|
18.3
|
%
|
|
16.6
|
%
|
|
|
Three Months Ended
|
|
Nine Months Ended
|
|
||||||||
|
|
July 4,
2015 |
|
June 28,
2014 |
|
July 4,
2015 |
|
June 28,
2014 |
|
||||
|
Net sales
|
100.0
|
%
|
|
100.0
|
%
|
|
100.0
|
%
|
|
100.0
|
%
|
|
|
Cost of sales
|
58.2
|
%
|
|
62.2
|
%
|
|
58.8
|
%
|
|
60.6
|
%
|
|
|
Gross profit
|
41.8
|
%
|
|
37.8
|
%
|
|
41.2
|
%
|
|
39.4
|
%
|
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
||||
|
Research and development
|
11.3
|
%
|
|
9.7
|
%
|
|
10.4
|
%
|
|
10.2
|
%
|
|
|
Selling, general and administrative
|
19.2
|
%
|
|
19.0
|
%
|
|
19.2
|
%
|
|
19.7
|
%
|
|
|
Impairment of investment
|
1.1
|
%
|
|
—
|
%
|
|
0.3
|
%
|
|
—
|
%
|
|
|
Amortization of intangible assets
|
0.3
|
%
|
|
0.4
|
%
|
|
0.3
|
%
|
|
0.5
|
%
|
|
|
Total operating expenses
|
31.9
|
%
|
|
29.1
|
%
|
|
30.2
|
%
|
|
30.4
|
%
|
|
|
Income from operations
|
9.9
|
%
|
|
8.7
|
%
|
|
11.0
|
%
|
|
9.0
|
%
|
|
|
Other income (net)
|
(0.3
|
)%
|
|
(0.1
|
)%
|
|
0.1
|
%
|
|
0.1
|
%
|
|
|
Income before income taxes
|
9.6
|
%
|
|
8.6
|
%
|
|
11.1
|
%
|
|
9.1
|
%
|
|
|
Provision for income taxes
|
2.6
|
%
|
|
2.0
|
%
|
|
2.8
|
%
|
|
2.3
|
%
|
|
|
Net income
|
7.0
|
%
|
|
6.6
|
%
|
|
8.3
|
%
|
|
6.8
|
%
|
|
|
|
Three Months Ended
|
||||||||||||
|
|
July 4, 2015
|
|
June 28, 2014
|
||||||||||
|
|
Amount
|
|
Percentage
of total
net sales
|
|
Amount
|
|
Percentage
of total
net sales
|
||||||
|
Consolidated:
|
|
|
|
|
|
|
|
||||||
|
Microelectronics
|
$
|
93,014
|
|
|
49.4
|
%
|
|
$
|
94,935
|
|
|
48.3
|
%
|
|
OEM components and instrumentation
|
40,189
|
|
|
21.3
|
%
|
|
42,581
|
|
|
21.7
|
%
|
||
|
Materials processing
|
27,403
|
|
|
14.5
|
%
|
|
30,992
|
|
|
15.8
|
%
|
||
|
Scientific and government programs
|
27,896
|
|
|
14.8
|
%
|
|
28,009
|
|
|
14.2
|
%
|
||
|
Total
|
$
|
188,502
|
|
|
100.0
|
%
|
|
$
|
196,517
|
|
|
100.0
|
%
|
|
|
Nine Months Ended
|
||||||||||||
|
|
July 4, 2015
|
|
June 28, 2014
|
||||||||||
|
|
Amount
|
|
Percentage
of total
net sales
|
|
Amount
|
|
Percentage
of total
net sales
|
||||||
|
Consolidated:
|
|
|
|
|
|
|
|
||||||
|
Microelectronics
|
$
|
294,094
|
|
|
49.6
|
%
|
|
$
|
281,744
|
|
|
47.8
|
%
|
|
OEM components and instrumentation
|
125,470
|
|
|
21.2
|
%
|
|
128,620
|
|
|
21.8
|
%
|
||
|
Materials processing
|
85,513
|
|
|
14.4
|
%
|
|
86,516
|
|
|
14.7
|
%
|
||
|
Scientific and government programs
|
87,761
|
|
|
14.8
|
%
|
|
92,415
|
|
|
15.7
|
%
|
||
|
Total
|
$
|
592,838
|
|
|
100.0
|
%
|
|
$
|
589,295
|
|
|
100.0
|
%
|
|
|
Three Months Ended
|
||||||||||||
|
|
July 4, 2015
|
|
June 28, 2014
|
||||||||||
|
|
Amount
|
|
Percentage
of total
net sales
|
|
Amount
|
|
Percentage
of total
net sales
|
||||||
|
Consolidated:
|
|
|
|
|
|
|
|
||||||
|
Specialty Lasers and Systems (SLS)
|
$
|
123,341
|
|
|
65.4
|
%
|
|
$
|
137,590
|
|
|
70.0
|
%
|
|
Commercial Lasers and Components (CLC)
|
65,161
|
|
|
34.6
|
%
|
|
58,927
|
|
|
30.0
|
%
|
||
|
Total
|
$
|
188,502
|
|
|
100.0
|
%
|
|
$
|
196,517
|
|
|
100.0
|
%
|
|
|
Nine Months Ended
|
||||||||||||
|
|
July 4, 2015
|
|
June 28, 2014
|
||||||||||
|
|
Amount
|
|
Percentage
of total
net sales
|
|
Amount
|
|
Percentage
of total
net sales
|
||||||
|
Consolidated:
|
|
|
|
|
|
|
|
||||||
|
Specialty Lasers and Systems (SLS)
|
$
|
408,448
|
|
|
68.9
|
%
|
|
$
|
418,208
|
|
|
71.0
|
%
|
|
Commercial Lasers and Components (CLC)
|
184,390
|
|
|
31.1
|
%
|
|
171,087
|
|
|
29.0
|
%
|
||
|
Total
|
$
|
592,838
|
|
|
100.0
|
%
|
|
$
|
589,295
|
|
|
100.0
|
%
|
|
|
Three Months Ended
|
||||||||||||
|
|
July 4, 2015
|
|
June 28, 2014
|
||||||||||
|
|
Amount
|
|
Percentage of
total net sales
|
|
Amount
|
|
Percentage of
total net sales
|
||||||
|
|
(Dollars in thousands)
|
||||||||||||
|
Research and development
|
$
|
21,270
|
|
|
11.3
|
%
|
|
$
|
19,046
|
|
|
9.7
|
%
|
|
Selling, general and administrative
|
36,154
|
|
|
19.2
|
%
|
|
37,226
|
|
|
19.0
|
%
|
||
|
Impairment of investment
|
2,017
|
|
|
1.1
|
%
|
|
—
|
|
|
—
|
%
|
||
|
Amortization of intangible assets
|
647
|
|
|
0.3
|
%
|
|
841
|
|
|
0.4
|
%
|
||
|
Total operating expenses
|
$
|
60,088
|
|
|
31.9
|
%
|
|
$
|
57,113
|
|
|
29.1
|
%
|
|
|
Nine Months Ended
|
||||||||||||
|
|
July 4, 2015
|
|
June 28, 2014
|
||||||||||
|
|
Amount
|
|
Percentage of
total net sales
|
|
Amount
|
|
Percentage of
total net sales
|
||||||
|
|
(Dollars in thousands)
|
||||||||||||
|
Research and development
|
$
|
61,467
|
|
|
10.4
|
%
|
|
$
|
60,396
|
|
|
10.2
|
%
|
|
Selling, general and administrative
|
113,777
|
|
|
19.2
|
%
|
|
116,413
|
|
|
19.7
|
%
|
||
|
Impairment of investment
|
2,017
|
|
|
0.3
|
%
|
|
—
|
|
|
—
|
%
|
||
|
Amortization of intangible assets
|
2,009
|
|
|
0.3
|
%
|
|
2,691
|
|
|
0.5
|
%
|
||
|
Total operating expenses
|
$
|
179,270
|
|
|
30.2
|
%
|
|
$
|
179,500
|
|
|
30.4
|
%
|
|
|
Nine Months Ended
|
||||||
|
|
July 4,
2015 |
|
June 28,
2014 |
||||
|
|
(in thousands)
|
||||||
|
Net cash provided by operating activities
|
$
|
68,835
|
|
|
$
|
64,897
|
|
|
Sales of shares under employee stock plans
|
7,256
|
|
|
10,513
|
|
||
|
Repurchases of common stock
|
(25,009
|
)
|
|
—
|
|
||
|
Capital expenditures
|
(16,187
|
)
|
|
(17,862
|
)
|
||
|
|
July 4, 2015
|
|
September 27, 2014
|
||||
|
|
(in thousands)
|
||||||
|
Cash and cash equivalents
|
$
|
103,138
|
|
|
$
|
91,217
|
|
|
Short-term investments
|
233,628
|
|
|
227,058
|
|
||
|
Working capital
|
581,156
|
|
|
563,736
|
|
||
|
|
Average Contract
Rate
|
|
U.S. Notional
Contract Value
|
|
U.S.
Fair Value
|
|||||
|
Non-Designated - For US Dollars
|
|
|
|
|
|
|||||
|
Euro
|
1.1059
|
|
|
$
|
(20,672
|
)
|
|
$
|
73
|
|
|
Japanese Yen
|
124.6394
|
|
|
$
|
(2,449
|
)
|
|
$
|
32
|
|
|
British Pound
|
1.5239
|
|
|
$
|
3,604
|
|
|
$
|
(90
|
)
|
|
Korean Won
|
1,116.4200
|
|
|
$
|
11,073
|
|
|
$
|
86
|
|
|
Chinese Renminbi
|
6.1410
|
|
|
$
|
10,051
|
|
|
$
|
(36
|
)
|
|
Singaporian Dollar
|
1.3673
|
|
|
$
|
(1,828
|
)
|
|
$
|
26
|
|
|
Malaysian Ringgit
|
3.6996
|
|
|
$
|
940
|
|
|
$
|
19
|
|
|
|
|
|
|
|
|
|||||
|
Non- Designated - For Euros:
|
|
|
|
|
|
|||||
|
Japanese Yen
|
124.7254
|
|
|
$
|
5,395
|
|
|
$
|
(11
|
)
|
|
|
|
|
|
|
|
|||||
|
Designated - For Euros
|
|
|
|
|
|
|||||
|
Japanese Yen
|
120.763
|
|
|
$
|
2,821
|
|
|
$
|
83
|
|
|
|
|
|
|
|
|
|||||
|
(i)
|
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
|
|
(ii)
|
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and
|
|
(iii)
|
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.
|
|
•
|
general economic uncertainties in the macroeconomic and local economies facing us, our customers and the markets we serve;
|
|
•
|
fluctuations in demand for our products or downturns in the industries that we serve;
|
|
•
|
the ability of our suppliers, both internal and external, to produce and deliver components and parts, including sole or limited source components, in a timely manner, in the quantity, quality and prices desired;
|
|
•
|
the timing of receipt and conversion of bookings to net sales;
|
|
•
|
the concentration of a significant amount of our backlog, and resultant net sales, with a few customers;
|
|
•
|
cancellation of customer orders and rescheduling of shipments;
|
|
•
|
fluctuations in our product mix;
|
|
•
|
the ability of our customers' other suppliers to provide sufficient material to support our customers' products;
|
|
•
|
currency fluctuations and stability, in particular the Euro, the Japanese Yen, the Korean Won, the Chinese Renminbi and the US dollar as compared to other currencies;
|
|
•
|
commodity pricing;
|
|
•
|
introductions of new products and product enhancements by our competitors, entry of new competitors into our markets, pricing pressures and other competitive factors;
|
|
•
|
our ability to develop, introduce, manufacture and ship new and enhanced products in a timely manner without defects;
|
|
•
|
our ability to manage our capacity and that of our suppliers;
|
|
•
|
our reliance on contract manufacturing;
|
|
•
|
the rate of market acceptance of our new products;
|
|
•
|
the ability of our customers to pay for our products;
|
|
•
|
expenses associated with acquisition-related activities;
|
|
•
|
seasonal sales trends;
|
|
•
|
access to applicable credit markets by us, our customers and their end customers;
|
|
•
|
delays or reductions in customer purchases of our products in anticipation of the introduction of new and enhanced products by us or our competitors;
|
|
•
|
our ability to control expenses;
|
|
•
|
the level of capital spending of our customers;
|
|
•
|
potential excess and/or obsolescence of our inventory;
|
|
•
|
costs and timing of adhering to current and developing governmental regulations and reviews relating to our products and business;
|
|
•
|
costs related to acquisitions of technology or businesses;
|
|
•
|
impairment of goodwill, intangible assets and other long-lived assets;
|
|
•
|
our ability to meet our expectations and forecasts and those of public market analysts and investors;
|
|
•
|
the availability of research funding by governments with regard to our customers in the scientific business, such as universities;
|
|
•
|
continued government spending on defense-related projects where we are a subcontractor;
|
|
•
|
maintenance of supply relating to products sold to the government on terms which we would prefer not to accept;
|
|
•
|
changes in policy, interpretations, or challenges to the allowability of costs incurred under government cost accounting standards;
|
|
•
|
damage to our reputation as a result of coverage in social media, Internet blogs or other media outlets;
|
|
•
|
managing our and other parties' compliance with contracts in multiple languages and jurisdictions;
|
|
•
|
managing our internal and third party sales representatives and distributors, including compliance with all applicable laws;
|
|
•
|
impact of government economic policies on macroeconomic conditions;
|
|
•
|
costs and expenses from litigation;
|
|
•
|
costs associated with designing around or payment of licensing fees associated with issued patents in our fields of business;
|
|
•
|
government support of alternative energy industries, such as solar;
|
|
•
|
the future impact of legislation, rulemaking, and changes in accounting, tax, defense procurement, or export policies; and
|
|
•
|
distraction of management related to acquisition or divestment activities.
|
|
•
|
loss of customers or orders;
|
|
•
|
increased costs of product returns and warranty expenses;
|
|
•
|
damage to our brand reputation;
|
|
•
|
failure to attract new customers or achieve market acceptance;
|
|
•
|
diversion of development, engineering and manufacturing resources; and
|
|
•
|
legal actions by our customers and/or their end users.
|
|
•
|
longer accounts receivable collection periods;
|
|
•
|
the impact of recessions and other economic conditions in economies outside the United States;
|
|
•
|
unexpected changes in regulatory requirements;
|
|
•
|
certification requirements;
|
|
•
|
environmental regulations;
|
|
•
|
reduced protection for intellectual property rights in some countries;
|
|
•
|
potentially adverse tax consequences;
|
|
•
|
political and economic instability;
|
|
•
|
import/export regulations, tariffs and trade barriers;
|
|
•
|
compliance with applicable United States and foreign anti-corruption laws;
|
|
•
|
cultural and management differences;
|
|
•
|
reliance in some jurisdictions on third party sales channel partners;
|
|
•
|
preference for locally produced products; and
|
|
•
|
shipping and other logistics complications.
|
|
•
|
stop manufacturing, selling or using our products that use the infringed intellectual property;
|
|
•
|
obtain from the owner of the infringed intellectual property right a license to sell or use the relevant technology, although such license may not be available on reasonable terms, or at all; or
|
|
•
|
redesign the products that use the technology.
|
|
•
|
issue stock that would dilute our current stockholders' percentage ownership;
|
|
•
|
pay cash that would decrease our working capital;
|
|
•
|
incur debt;
|
|
•
|
assume liabilities; or
|
|
•
|
incur expenses related to impairment of goodwill and amortization.
|
|
•
|
problems combining the acquired operations, systems, technologies or products;
|
|
•
|
an inability to realize expected operating efficiencies or product integration benefits;
|
|
•
|
difficulties in coordinating and integrating geographically separated personnel, organizations, systems and facilities;
|
|
•
|
difficulties integrating business cultures;
|
|
•
|
unanticipated costs or liabilities, including the costs associated with improving the internal controls of the acquired company;
|
|
•
|
diversion of management's attention from our core businesses;
|
|
•
|
adverse effects on existing business relationships with suppliers and customers;
|
|
•
|
potential loss of key employees, particularly those of the purchased organizations;
|
|
•
|
incurring unforeseen obligations or liabilities in connection with acquisitions; and
|
|
•
|
the failure to complete acquisitions even after signing definitive agreements which, among other things, would result in the expensing of potentially significant professional fees and other charges in the period in which the acquisition or negotiations are terminated.
|
|
•
|
maintaining and enhancing our relationships with our customers;
|
|
•
|
the education of potential end-user customers about the benefits of lasers and laser systems; and
|
|
•
|
our ability to accurately predict and develop our products to meet industry standards.
|
|
•
|
the ability of our Board of Directors to alter our bylaws without stockholder approval;
|
|
•
|
limiting the ability of stockholders to call special meetings; and
|
|
•
|
establishing advance notice requirements for nominations for election to our Board of Directors or for proposing matters that can be acted on by stockholders at stockholder meetings.
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
31.1
|
|
Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
31.2
|
|
Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
32.1
|
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
32.2
|
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
101.INS*
|
|
XBRL Instance Document
|
|
|
|
|
|
101.SCH*
|
|
XBRL Taxonomy Extension Schema
|
|
|
|
|
|
101.CAL*
|
|
XBRL Taxonomy Extension Calculation Linkbase
|
|
|
|
|
|
101.DEF*
|
|
XBRL Taxonomy Extension Definition Linkbase
|
|
|
|
|
|
101.LAB*
|
|
XBRL Taxonomy Extension Label Linkbase
|
|
|
|
|
|
101.PRE*
|
|
XBRL Taxonomy Extension Presentation Linkbase
|
|
*
|
|
In accordance with Rule 406T of Regulation S-T, the information in these exhibits is furnished and deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Exchange Act of 1934, and otherwise is not subject to liability under these sections.
|
|
|
|
|
|
|
|
Coherent, Inc.
|
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
Date:
|
August 12, 2015
|
/s/:
|
JOHN R. AMBROSEO
|
|
|
|
|
John R. Ambroseo
|
|
|
|
|
President and Chief Executive Officer
|
|
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
Date:
|
August 12, 2015
|
/s/:
|
HELENE SIMONET
|
|
|
|
|
Helene Simonet
|
|
|
|
|
Executive Vice President and Chief Financial Officer
|
|
|
|
|
(Principal Financial and Accounting Officer)
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
31.1
|
|
Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
31.2
|
|
Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
32.1
|
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
32.2
|
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
101.INS*
|
|
XBRL Instance Document
|
|
|
|
|
|
101.SCH*
|
|
XBRL Taxonomy Extension Schema
|
|
|
|
|
|
101.CAL*
|
|
XBRL Taxonomy Extension Calculation Linkbase
|
|
|
|
|
|
101.DEF*
|
|
XBRL Taxonomy Extension Definition Linkbase
|
|
|
|
|
|
101.LAB*
|
|
XBRL Taxonomy Extension Label Linkbase
|
|
|
|
|
|
101.PRE*
|
|
XBRL Taxonomy Extension Presentation Linkbase
|
|
*
|
|
In accordance with Rule 406T of Regulation S-T, the information in these exhibits is furnished and deemed not filed or part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Exchange Act of 1934, and otherwise is not subject to liability under these sections.
|
|
|
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|